SecBot SecBot
8-K ·Filed Aug 3, 2026

TWST

Twist Bioscience Corp
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001581280-26-000044
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat-and-raise quarter with accelerating revenue growth (23% YoY) and expanding gross margins signals improving operating leverage. Traders should watch for the Q4 FY26 adjusted EBITDA breakeven milestone and any early FY2027 guidance on the upcoming earnings call, which could drive further upside.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$101.06
T+0 close · Aug 3, 2026 · via day close
Latest settled
+55.24%
T+60 · $156.89
Vs SPY
+53.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $101.06entry
  2. T+1 · 4mo ago −1.59%α −3.40% · $99.45
  3. T+5 · 3mo ago +23.57%α +21.54% · $124.88
  4. T+20 · 3mo ago +37.54%α +36.30% · $139.00
  5. T+60 · 21d ago +55.24%α +53.46% · $156.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate. The company raised its full-year FY2026 revenue guidance to $456-457M, up $12M at the midpoint from prior guidance of $442-447M, while reiterating Q4 FY26 adjusted EBITDA breakeven. Gross margin expanded to 52.8%, up 120 bps sequentially, and the company posted its 14th consecutive quarter of sequential growth, reinforcing strong execution in both DSPS (+39% YoY) and NGS (+12% YoY) segments.

Key Financial Metrics

EPS
−$0.56
est −$0.18 · -211.1%
Revenue
$118.4M
est $114.5M · +3.4% · +23.2% YoY
Rating
strong beat
Guidance
$456M-$457M
raised
Gross Margin
52.8%

Key Facts

  • Revenue of $118.4M beat consensus of $114.5M and grew 23% YoY from $96.1M.
  • FY2026 revenue guidance raised to $456-457M from $442-447M, an increase of ~$12M at the midpoint.
  • Gross margin improved to 52.8% from 51.6% in Q2 FY26, a sequential increase of 120 bps.
  • DSPS revenue grew 39% YoY to $56.6M; NGS revenue grew 12% YoY to $61.8M.
  • Adjusted EBITDA loss of $(11.3)M vs $(8.0)M in the prior year period; company reiterates Q4 FY26 adjusted EBITDA breakeven.
  • Cash and short-term investments stood at $167M as of June 30, 2026.
  • GAAP net loss was $(35.1)M or $(0.56) per diluted share, compared to net income of $20.4M in Q3 FY25 which included a $48.8M gain from the spin-out of Atlas Data Storage.

Financial Impact

Revenue beat consensus by ~$3.9M (3.4%); FY guidance raised by ~$12M at the midpoint; gross margin expanded 120 bps sequentially.

revenuegross marginguidanceadjusted EBITDA

Risk Factors

  • GAAP net loss continues to widen on an absolute basis ($35.1M vs $20.4M net income in prior year, though prior year included a $48.8M one-time gain).
  • Cash burn remains elevated; cash and short-term investments declined from $172M at March 31, 2026 to $167M at June 30, 2026.
  • SG&A expenses grew 27% YoY to $80.7M, outpacing revenue growth of 23%.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001581280-26-000044
Document: twist-20260803.htm0001581280-26-000044
Document: 0001581280-26-000044-index-headers.html0001581280-26-000044
Document: 0001581280-26-000044-index.html0001581280-26-000044
Document: 0001581280-26-000044.txt0001581280-26-000044
8-K Data (Synthetic)0001581280-26-000044

US Market Status

Market Closed · Opens Wed (12h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026